Company Filing History:
1 out of 833,002 Years Active: 2009
Title: David Ragsdale: Innovator in Epilepsy Research
Introduction
David Ragsdale is a prominent inventor based in Montreal, Canada. He has made significant contributions to the field of epilepsy research, particularly through his innovative patent related to idiopathic generalized epilepsy.
Latest Patents
David Ragsdale holds a patent titled "SCN3A locus for idiopathic generalized epilepsy, mutations thereof and method using same." This invention focuses on the identification of three genes mapping to chromosome 2 that exhibit mutations in patients with epilepsy. The patent encompasses nucleic acid sequences and protein sequences of these loci (SCNA) and their applications in assessing, diagnosing, prognosing, or treating epilepsy. It also aims to predict an epileptic individual's response to medication and identify agents that can modulate the function of the SCNA. Furthermore, the invention provides screening assays using SCN1A, SCN2A, and/or SCN3A to identify compounds with therapeutic benefits for epilepsy and related neurological disorders.
Career Highlights
Throughout his career, David Ragsdale has focused on advancing the understanding of epilepsy and its genetic underpinnings. His work has been instrumental in paving the way for new diagnostic and therapeutic approaches in the field.
Collaborations
David has collaborated with notable colleagues, including Guy A Rouleau and Ronald G Lafreniere, to further enhance the impact of his research and innovations.
Conclusion
David Ragsdale's contributions to epilepsy research through his patent highlight the importance of genetic understanding in developing effective treatments. His work continues to inspire advancements in the field of neurology.